Consolidated Statements of Cash Flows	12 Months Ended
	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Cash flow from operating activities:
Net loss	$ (13,983,967)	$ (25,737,634)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	739,316	1,313,075
Vesting expense	2,038	166,312
Common stock issued to non-employees	299,430	356,125
Gain on valuation of equity-linked instruments and derivative liability	(12,457)	(115,647)
Loss on impairment of goodwill	0	7,231,093
Loss on impairment of finite-lived intangible assets	0	3,349,375
Loss on impairment of property and equipment	162,905	185,469
Loss on property and equipment disposal	903	14,346
us-gaap_IncreaseDecreaseInAccountsReceivable	2,501	(23,000)
Inventories	(63,881)	(42,808)
Prepaid expense and other assets	(43,377)	78,425
Accounts payable	398,575	(78,322)
Accrued expenses and other liabilities	(397,851)	869,987
Contract liabilities	(293,982)	41,819
Other long-term liabilities	5,459	(25,415)
Net cash used in operating activities:	(13,189,390)	(12,370,800)
Cash flow from investing activities:
Purchase of property and equipment	(276,352)	(419,869)
Acquisition of intangibles	(26,019)	(55,828)
Net cash used in investing activities	(302,371)	(475,697)
us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract
Proceeds from issuance of common stock and warrants, net	0	6,507,050
Proceeds from issuance of common stock pursuant to equity line	0	236,009
Repurchase of common stock upon vesting of restricted stock units	(1,510)	(27,654)
Proceeds from note payable	364,721	0
Repayment of note payable	(214,313)	0
Net cash provided by financing activities	148,898	6,715,405
Net decrease in cash	(13,342,863)	(6,131,092)
Cash at beginning of period	22,071,523	28,202,615
Cash at end of period	8,728,660	22,071,523
us-gaap_SupplementalCashFlowInformationAbstract
Cash payments for interest	13,904	3,821
Adjustment to goodwill for acquisition of zPREDICTA contract liabilities	0	373,303
Right-of-use assets obtained in exchange for lease liabilities	2,997,181	0
Series F Preferred Stock dividend	794	0
Common stock issued to settle accrued board of directors’ and advisory board compensation	189,896	0
Redemption of Series F Preferred Stock	(794)	0
Restricted Stock Units (RSUs) [Member]
us-gaap_SupplementalCashFlowInformationAbstract
Common stock issued to settle accrued board of directors’ and advisory board compensation	4,934	0
Reverse Stock Split [Member]
us-gaap_SupplementalCashFlowInformationAbstract
Common stock issued to settle accrued board of directors’ and advisory board compensation	$ 253	$ 0